ANTIBODIES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Antibodies Market is estimated to be valued at USD 3,23,043.7 Mn in 2026 and is expected to reach USD 7,64,714.8 Mn in 2033, exhibiting a compound annual growth rate (CAGR) of 13.1% from 2026 to 2033.

Analysts’ Views on Global Antibodies Market:

Increasing inorganic strategies such as collaborations by the key market players is expected to drive the global antibodies market over the forecast period. For instance, in March 2022, Sanofi, a pharmaceutical and healthcare company, and Seagen Inc., a biotechnology company, announced a collaboration agreement, to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology

Figure 1. Global Antibodies Market Share (%), By Drug Type, 2026

Global Antibodies Market – Driver

Increase in inorganic strategies

Increasing inorganic strategies such as collaboration by the key market players is expected to drive the global antibodies market over the forecast period. For instance, in September 2020, Eli Lilly and Company, a pharmaceutical company and Amgen, an U.S.

Figure 2. Global Antibodies Market Value (US$ Million), By Region , 2026

Global Antibodies Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global antibodies market over the forecast period.   

The U.S. government has placed a pre-order for 100 million doses of Pfizer's BNT162b2 mRNA vaccine at a cost of $1.95 billion as early as July 22, 2020, and after one year, it has already placed orders for a total of 500 million doses.

Global Antibodies Market Segmentation:

The global antibodies market report is segmented into Drug Type, Disease Indication, End User, and Region

Based on Drug Type, the market is segmented into monoclonal antibodies, polyclonal antibodies, and antibody-drug complexes (ADCs). Out which the monoclonal antibodies segment is expected to hold a dominant position in the antibodies market over the forecast period.

Based Disease Indication, the antibodies market is segmented into CNS disorders, cardiovascular diseases, cancer, and autoimmune disorders.

Based on End User, the antibodies market is segmented into hospitals, long-term care facilities, and research institutes.

Global Antibodies Market Cross Sectional Analysis:

In drug type, the monoclonal antibodies segment is expected to hold a dominant position in the global antibodies market in North America over the forecast period. For instance, in October 2020, the U.S.

Global Antibodies Market: Key Developments

For instance, in October 2020, IAVI, a nonprofit scientific research organization, and Serum Institute of India Pvt.

Global Antibodies Market: Key Trends

Increasing authorizations for antibodies by the regulatory authorities

Increasing authorizations by the regulatory authorities is expected to drive the global antibodies market over the forecast period. For instance, in May 2021, Roche India, announced that the Central Drugs Standards Control Organization (CDSCO) has provided an Emergency Use Authorization (EUA) for Roche’s antibody cocktail (Casirivimab and Imdevimab) in India.

Global Antibodies Market: Restraint

Side effects associated with the antibodies

Use of antibodies may lead to some side effects such as serum sickness, acute anaphylaxis, and specific target-related adverse effects, which is also expected to hinder the market growth. To overcome the adverse effects of the drugs and antibodies, regulatory authorities should strictly monitor the products.

Global Antibodies Market - Key Players

Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Lilly., Iovance Biotherapeutics, Inc., Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd.

*Definition: An antibody, also called immunoglobulin, is a protein produced by plasma cells in response to specific antigens. These antibodies can be used as therapeutic as well as diagnostic purposes for several indications, including cancers, autoimmune disorders, inflammatory & infectious diseases, and others.